AIxMed Raises $2.75M in SAFE Funding

▤ Summary

Fundraising proceeds will be used to add a Chief Medical Officer to its leadership team and to support validation studies prior to FDA submission. Led by CEO Samuel Chen, AIxMed helps pathologists digitize cytology samples in minutes and extract clinical insights in seconds to improve patient diagnosis and care. Its first application, AIxURO, is an AI-assisted urine cytology imaging and reporting software package for bladder cancer diagnosis and surveillance based on The Paris System (TPS). The company has recently concluded a pilot study and the results were published in Cancer Cytopathology. The next fundraising series to support commercialization efforts is slated for late 2023.

▦ Linked Companies